Abstract

Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient

Author(s): Bramwell Bethany

Issue: Jul/Aug 2011 - Volume 15, Number 4

Page(s): 316-319

Download in electronic PDF format for $75
  • Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 1
  • Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 2
  • Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 3
  • Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 4

Abstract

The incidence of primary phenylketonuria in the U.S. is approximately 1 in 15,000 births. It is most common in whites, occurring in approximately 1 in 10,000 newborns. Tetrahydrobiopterin deficiency represents 1.5% to 2% of phenylketonuria cases, affecting approximately 1 in 1 million newborns. Most children with tetrahydrobiopterin deficiency are normal at birth, but, as phenylalanine accumulates, the child slowly develops cognitive and motor signs and symptoms resulting in severe mental retardation. In addition to intellectual disability, if untreated, progressive problems with development, movement disorders, difficulty swallowing, seizures, behavioral problems, and an inability to control body temperature will develop. Diagnosis and treatment is essential as early in life as possible to prevent irreversible neurological damage. If appropriate treatment is initiated in the first days of life, all manifestations of the disease can be prevented and patients can reach adult age with good outcomes.

Related Keywords

  • tetrahydrobiopterin deficiency
  • BH4
  • primary phenylketonuria
  • phenylalanine accumulation
  • newborn infant
  • neonate
  • genetic inborn errors of metabolism
  • PKU
  • neurologic disorders
  • cognitive deficits
  • metabolic disorder
  • nitric oxide
  • dopamine
  • serotonin
  • carbidopa
  • levodopa
  • 5-hydroxytryptophan
  • 5-HTP
  • folinic acid
  • saptropterin dihydrochloride
  • selegiline hydrochloride
  • neurotransmitters
  • formulations
  • leucovorin

Related Categories

  • FORMULATIONS
  • MENTAL HEALTH
  • NUTRITION AND NUTRICEUTICALS
  • PEDIATRICS
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2011
Pg. 316-319
Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient
Author(s): Bramwell Bethany
Jul/Aug 2003
Pg. 266-270
Sensitization Therapy for Warts
Author(s): Kuntz Rachael
Mar/Apr 2004
Pg. 96-99
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2
Author(s): Cutter Christopher B
Mar/Apr 1997
Pg. 84-86
Compounding for the Pediatric Patient
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Jan/Feb 2004
Pg. 16-21
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1
Author(s): Cutter Christopher B
Jul/Aug 1999
Pg. 309-310
Acidifying Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Jul/Aug 2019
Pg. 324-331
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
Author(s): de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro
Nov/Dec 2000
Pg. 429-431
Testosterone Deficiency in Men: New Treatments for Andropause
Author(s): Biundo Bruce, Shippen Eugene
Jan/Feb 2001
Pg. 6-8
Pediatric Compounding: Coloring Outside the Lines
Author(s): Preckshot John
Nov/Dec 2000
Pg. 440-441
Managing Zinc Deficiency in an Office Setting
Author(s): Norwood Charles, Chaney Bill, Moore Robert W
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Sep/Oct 2000
Pg. 334
Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome
Author(s): Mathews Elizabeth
Nov/Dec 2003
Pg. 490-494
Patient Interest in Pharmacist-Provided Menopause and Hormone Replacement Therapy Consultations
Author(s): Branvold Andrea, Barner Jamie C
Mar/Apr 2019
Pg. 94-104
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Author(s): Zur Eyal
Jan/Feb 2019
Pg. 23-31
Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Author(s): Zur Eyal
Sep/Oct 2015
Pg. 410
Trichloroacetic Acid 20%, Salicylic Acid 20%, Lactic Acid 10% in Flexible Collodion
Author(s): Allen Loyd V Jr
May/Jun 2007
Pg. 244
Folic Acid 1-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Jan/Feb 2001
Pg. 9-12
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Author(s): Schotik Debora
Jul/Aug 1999
Pg. 274-276
Extemporaneous Formulations in Pediatric Patients
Author(s): Nahata Milap C